Charles Schwab Investment Management Inc. Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Charles Schwab Investment Management Inc. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,201,899 shares of the medical research company's stock after selling 14,728 shares during the period. Charles Schwab Investment Management Inc. owned about 0.66% of IQVIA worth $284,814,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of IQV. Versant Capital Management Inc lifted its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA during the second quarter valued at approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the third quarter worth $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA in the 2nd quarter worth $29,000. Institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Performance

Shares of NYSE IQV traded up $4.22 during trading on Friday, reaching $201.82. 1,887,846 shares of the company traded hands, compared to its average volume of 2,206,617. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a 50 day simple moving average of $222.67 and a 200-day simple moving average of $227.18. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock has a market capitalization of $36.63 billion, a PE ratio of 26.49, a P/E/G ratio of 2.03 and a beta of 1.51.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Morgan Stanley cut their target price on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a "buy" rating and a $276.00 target price for the company. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th. TD Cowen lowered their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.